GlycoMimetics Announces Plans to Initiate Breast Cancer Trial to Evaluate GMI-1359
GlycoMimetics, Inc. (GLYC)
Last glycomimetics, inc. earnings: 5/1 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.glycomimetics.com/investor-relations
Company Research
Source: Business Wire
Proof-of-concept trial to evaluate safety and biomarkers of cancer cell mobilization in patients with hormone receptor positive metastatic breast cancer Novel GlycoMimetics drug candidate targets tumor and bone marrow microenvironments ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced plans to initiate a clinical trial of GMI-1359 in breast cancer patients whose tumors have spread to bone. GMI-1359 is a dual function antagonist that targets both E-selectin and CXCR4, both of which are involved in tumor trafficking and metastatic spread. The trial will evaluate dose escalation as well as safety and pharmacodynamic markers in these patients. The trial’s Co-Principal Investigators are Kelly Marcom, M.D., and Dorothy Sipkins, M.D., Ph.D., both of the Duke Cancer Institute. Dr. Sipkins has previously published on the key roles of bot
Show less
Read more
Impact Snapshot
Event Time:
GLYC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLYC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLYC alerts
High impacting GlycoMimetics, Inc. news events
Weekly update
A roundup of the hottest topics
GLYC
News
- GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024Business Wire
- Loss-Making GlycoMimetics, Inc. (NASDAQ:GLYC) Expected To Breakeven In The Medium-Term [Yahoo! Finance]Yahoo! Finance
- GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- GlycoMimetics, Inc. (NASDAQ: GLYC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
GLYC
Earnings
- 3/27/24 - Beat
GLYC
Analyst Actions
- 3/27/24 - HC Wainwright
GLYC
Sec Filings
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- GLYC's page on the SEC website